Linked Life Data

6559107

Source:http://linkedlifedata.com/resource/pubmed/id/6559107

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1984-3-21
pubmed:abstractText
Normal human serum contains an inhibitor of complement which is distinguished by its small size of 500 daltons, the low molecular weight inhibitor (LMWI). When LMWI was present during incubation of zymosan or cobra venom factor with serum, formation of complement reactive complexes was blocked as measured by failure of these mixtures to lyse susceptible erythrocytes from patients with paroxysmal nocturnal haemoglobinuria (PNH). Addition of LMWI to pre-formed complexes had no effect on their subsequent haemolytic activity. When dialysis was used to remove LMWI from reaction mixtures, it was shown that LMWI had not irreversibly altered any of the complement components. Purified components were used to demonstrate that LMWI prevented factor D activation of cobra venom factor-factor B complexes. LMWI also strongly inhibited binding of 125I-factor B to human erythrocytes bearing C3b and had little or nor effect on binding of 125I-factor H to the C3b bearing cells. Factor B binding to C3b was equally inhibited on normal and PNH erythrocytes. Thus, a dialysable fraction from normal human serum prevents activation of human complement by blocking formation, but not the activity of the C3/C5 convertase. These low molecular weight inhibitors result in inhibition of factor B binding to C3b and inhibition of factor D activation of C3bB complexes.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-1067618, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-123251, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-301546, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-4178758, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-4473995, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-457861, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-4630453, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-4713634, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-4981797, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-56780, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-5935361, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-62817, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-6450726, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-6773316, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-6912799, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-6915939, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-7175439, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-7359260, http://linkedlifedata.com/resource/pubmed/commentcorrection/6559107-894033
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0009-9104
pubmed:author
pubmed:issnType
Print
pubmed:volume
55
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
166-76
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
pubmed:publicationType
Journal Article